Estrogen & Testosterone in Perimenopause

Mar 28

Written By colton reid

Estrogen & Testosterone in Perimenopause — Patient Resource | Mercure

Mercure

Concierge Regenerative Medicine

Estrogen & Testosterone
in Perimenopause

Patient Education Resource · Healing from Within Series

This guide is for women in perimenopause (approximately ages 45–55) who are considering or currently using hormone therapy. It explains how estrogen and testosterone differ, what the evidence shows about benefits and risks, and what questions to bring to your next appointment.

Estrogen and Testosterone: Different Hormones, Different Roles

Hormone therapy is often discussed as a single treatment, but estrogen and testosterone address different symptoms, carry different risks, and are indicated for different reasons. Understanding the distinction is the foundation of making an informed decision.

Estrogen

Hot flashes & night sweats
Vaginal dryness & discomfort
Bone density protection
Mood & sleep stability
Cardiovascular lipid support

Testosterone

Sexual desire & motivation
Energy, drive, and vitality
Muscle tone & body composition
Cognitive sharpness & focus
Overall sense of wellbeing

Important: Many women on estrogen alone continue to experience fatigue, low drive, body composition changes, and cognitive fog — because these symptoms are primarily testosterone-mediated. Both hormones may need to be evaluated to address the full picture.

The Timing Window — Why Starting Earlier Matters for Estrogen

The risks and benefits of estrogen therapy are not the same at every age. Research consistently shows that women who begin estrogen therapy during perimenopause or within 10 years of their last period experience the most favorable balance of benefit and risk. This is called the critical window or timing hypothesis.

Perimenopause
Ages 45–52

Most favorable window. Cardiovascular & neuroprotection strongest. Risks well-characterized and low in healthy women.

Early post-menopause
Within 10 years

Generally favorable. Individual risk factors become more relevant. Supported by most major guidelines.

Late initiation
10+ years post-menopause

Risk-benefit balance shifts. Requires careful individual evaluation. Not contraindicated for all women, but the calculus changes significantly.

Benefits & Risks at a Glance

Estrogen (with progesterone if uterus intact)

What Changes	Direction	Context
Hot flashes & night sweats	Reduced	Well-established; primary FDA indication
Bone fracture risk	Reduced	Significant protective effect
Type 2 diabetes risk	Reduced	Consistent across studies
Colon cancer risk	Reduced	Observed in combined therapy data
Breast cancer risk	Modest increase	~1 extra case/1,000 women/year with combined therapy; risk profile varies by type and duration
Blood clot risk	Modest increase	Transdermal route carries lower risk than oral; ~2 extra cases/1,000 women/year
Stroke risk	Age-dependent	Lower risk in younger women in the critical window; increases with late initiation

Testosterone (off-label; physiologic dosing)

What Changes	Direction	Context
Sexual desire & satisfaction	Improved	Strong evidence; Global Consensus Statement 2019
Energy & general wellbeing	Improved	Acknowledged in 2019 Consensus; emerging trial data supports
Body composition	Favorable trend	Growing RCT evidence for lean mass support at physiologic doses
Cognitive function	Emerging signal	Observational & small trial data; larger studies ongoing
Acne / hair growth	Possible	Dose-dependent; typically indicates need for dose reduction; reversible
Cardiovascular (lipids)	Route-dependent	Oral route has unfavorable lipid effect; transdermal/subcutaneous routes do not

Note on the evidence base: Some patient education materials continue to state that testosterone does not improve energy, mood, body composition, or cognition. This reflects older literature. The 2019 Global Consensus Statement and subsequent data represent a meaningful update to that position. Ask your provider to discuss the current evidence with you.

Questions to Bring to Your Appointment

Am I in the critical window? Ask your provider where you are in perimenopause and whether you are in the timing window where estrogen's benefits are most favorable.

Has my testosterone been assessed? Specifically ask for free testosterone and SHBG — not just total testosterone, which can be misleading.

Which of my symptoms are estrogen-mediated vs. testosterone-mediated? This distinction should guide which therapy — or combination — is appropriate.

If I have a uterus, is progesterone being considered alongside estrogen? Systemic estrogen without progesterone in women with an intact uterus increases endometrial cancer risk.

What formulation and route are you recommending, and why? Transdermal routes carry a different risk profile than oral for both estrogen and testosterone.

What does monitoring look like? A clear follow-up plan with labs and symptom reassessment is part of responsible prescribing for both hormones.

If You Wish to Proceed: Next Steps

Complete baseline labs: Estradiol, FSH, total and free testosterone, SHBG, thyroid panel, lipid panel, and CBC as clinically indicated.
Discuss your full symptom picture: Both the symptoms that are most bothersome and those that have changed gradually over time — including energy, cognition, libido, and body composition.
Review your personal risk factors: Personal and family history of clotting disorders, hormone-sensitive cancers, cardiovascular disease, and liver disease are all relevant to the prescribing decision.
Agree on a monitoring plan: Follow-up labs at 6–8 weeks after initiation; ongoing reassessment of symptom response and side effects at each visit.
Revisit regularly: Hormone needs change over time. Therapy that is appropriate today should be reassessed periodically — not simply continued indefinitely without evaluation.

colton reid